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Abstract
The cardiac troponins are integral components of the myofibrillary
apparatus and they regulate muscle contraction. The measurement
of cardiac troponins has replaced other biomarkers for the specific
detection of myocardial necrosis and for the diagnosis of
myocardial infarction. The tissue specificity plus sensitivity of the
measurement technology has meant that cardiac damage can be
detected in circumstances other than conventional acute coronary
syndromes. The ability to specifically detect cardiac damage as
part of multiple organ failure in intensive care patients has been
shown to provide prognostic information, but it is unclear whether
this is a dependent or an independent marker of outcome.
In the present issue of Critical Care, King and colleagues
have examined the role of troponin as an outcome predictor
[1]. The troponins, troponin T and troponin I, are part of the
contractile apparatus of all striated muscles. Voltage changes
across the sarcolemmal membrane alter the intracellular
calcium concentrations that act as the coupling mechanism
to alter the conformation of the troponin–tropomyosin
complex. This complex acts as a molecular switch to regulate
muscle contraction and relaxation via activation or inhibition
of the actinomyosin ATPase.
There are tissue-specific isoforms of both troponin T and
troponin I in cardiac muscle: cardiac troponin T (cTnT) and
cardiac troponin I (cTnI). Rapid, sensitive immunoassays have
been developed for both cTnT and cTnI [2]. This has
produced a paradigm shift in the ability of the diagnostic
laboratory to diagnose myocardial infarction. A series of
landmark studies established that the measurement of cTnT
and cTnI was superior to the existing methods of biochemical
detection of myocardial infarction, the measurement of
creatine kinase and its MB isoenzyme (creatine kinase-MB).
Initial studies showed that cTnT and cTnI measurements
identified a high-risk group in patients where creatine
kinase-MB [3] or creatine kinase [4] measurement excluded
myocardial infarction. Subsequently, cTnT and cTnI
measurements on admission were shown to identify high-risk
groups [5,6] even in patients with ST-elevation myocardial
infarction [7]. The ability of cTnT and cTnI measurements to
diagnose myocardial infarction, to predict prognosis and to
guide management in patients admitted with acute coronary
syndromes (ACS) is now well documented. Measurement of
cTnT and cTnI is now included in the current guidelines for
diagnosis [8] and management [9] of ACS and myocardial
infarction, and other biomarkers are no longer recommended.
In addition to sensitivity, cTnT and cTnI measurements offer
absolute cardiospecificity. There is a misconception that
creatine kinase-MB is cardiospecific. This is not the case. In
situations where there is skeletal muscle damage, creatine
kinase and creatine kinase-MB are both elevated but cTnT
and cTnI are not [10,11]. The sensitivity and specificity of
cTnT and cTnI measurements have demonstrated that
elevations of both can be documented in a large range of
non-ACS populations [12], including patients in intensive
care. In such cases, the mechanism of troponin elevation was
initially suggested to be due to problems in the measurement
technology. This has been demonstrated not to be the case,
and it is recognised that non-ACS troponin elevations are
both true reflections of myocardial damage and associated
with an adverse prognosis [2]. Non-ACS elevations of
cardiac troponin may occur on a background of ischaemic
heart disease (secondary ischaemic cardiac injury) or as non-
ischaemic cardiac injury, although both situations may
coexist. The actual mechanism of cardiac damage is unclear.
It is possible that this might be previously unrecognised
microinfarction. In cocaine-induced cardiac damage, magnetic
resonance imaging demonstrates diffuse myocardial damage
associated with troponin elevation but no specific coronary
artery occlusion. Troponin elevation in this group is more
commonly associated with diffuse coronary artery disease
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[13]. It  has also been suggested that under conditions of
myocardial stress there may be ischaemia with intracellular
degradation of troponin and release of troponin fragments [14].
Whatever the mechanism, the elevation of cardiac troponins
in intensive care patients was described early [15]; this
finding has been replicated subsequently [16,17], including
by this study. All studies are consistent in acknowledging the
fact that elevation of cardiac troponin carries prognostic
significance. The disagreement within the literature concerns
whether the troponin elevation is an independent risk
predictor or whether it is an organ system failure marker. If the
latter, it would be expected to be a dependant variable within
an organ system failure score, and therefore a univariate
predictor rather than a multivariate predictor. There are
published data to support both arguments [18], as the
authors point out.
Is there a way out of this impasse? In a study of septic
patients who had troponin measurements and ventricular
function assessment by trans-oesophageal echocardio-
graphy, although mortality was predicted by cTnT and cTnI
elevation, multivariate analysis showed that the major
predictor of troponin elevation was left ventricular dysfunction
[19], consistent with previous reports [20]. It is therefore
probable that, for a given population, cardiac troponin as the
dominant predictor will be dictated by whether or not
ventricular dysfunction is the major contributor to mortality.
Given the different population mixes in different intensive care
units, it will be expected that different conclusions will be
drawn from different studies. The search for a single
biomarker that will be the Holy Grail for prognosis on
admission is seductive. The cardiac troponins are predictors
of mortality. Differences in demographics and case mix
across different intensive care units, as well as a lack of
standardisation of cTnI methods, make it probable that this
particular search for a Holy Grail will be similarly inconclusive —
occasional glimpses of the truth but no certainty.
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